XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.22.1

ACCRUED LIABILITIES | 3 Months Ended
--- | ---
Mar. 31, 2022
Payables and Accruals [Abstract] |
ACCRUED LIABILITIES | 3. ACCRUED LIABILITIES Accrued liabilities consisted of the following as of the dates noted in the table below:
|  | March 31, |  |  | December 31, |
(In thousands) |  | 2022 |  |  | 2021 |
CRO and clinical trial costs |  | $ | 22,567 |  |  | $ | 22,804 |
Manufacturing activities |  |  | 6,846 |  |  |  | 4,123 |
Professional legal and accounting fees |  |  | 5,435 |  |  |  | 2,030 |
Interest payable |  |  | 393 |  |  |  | 336 |
Other |  |  | 555 |  |  |  | 541 |
|  | $ | 35,796 |  |  | $ | 29,834 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration